Introduction {#S1}
============

Cessation of cocaine intake following chronic drug exposure is typically characterized by anxiety, depression, fatigue and agitation ([@R46]). Importantly, anxiety induced during early phases of cocaine abstinence is often a provoking factor leading to relapse to cocaine use in human addicts ([@R12]; [@R26]). Corticotropin-releasing factor (CRF) is a neuropeptide widely distributed in extrahypothalamic-limbic brain areas, such as the amygdala, and has been implicated in mediating the 'anxiety-like' behavior that is observed in animals during the initial phase of cocaine abstinence ([@R58]; [@R74]). Animal studies have demonstrated that CRF protein expression is significantly elevated in the amygdala, a brain region rich in numerous CRF neurons, during early cocaine withdrawal (2 days) from chronic cocaine exposure ([@R58]). Additionally, significant increases in amygdalar CRF gene expression have also been reported to occur in animals during this early withdrawal time-period ([@R74]). Taken together, these findings indicate amygdalar CRF as a potential substrate underlying the expression of anxiety-like behavior that has been exhibited by animals during early cocaine withdrawal ([@R74]).

The amygdala, a subcortical limbic structure that receives prominent noradrenergic innervation from the brainstem ([@R8]; [@R51]), shows a significant up-regulation of β~1~-adrenergic receptor expression following 2 days of withdrawal from chronic cocaine treatment ([@R56]). β~1~-adrenergic receptor expression levels return to that of controls following a more extended withdrawal period (12 days) ([@R56]). Interestingly, administration of the selective β~1~-adrenergic receptor antagonist, betaxolol ([@R45]), during early cocaine withdrawal significantly diminished cocaine withdrawal-related anxiety-like behavior in the animals and also reduced β~1~-adrenergic receptor expression levels such that they were comparable to controls ([@R56]). The β~1~-adrenergic receptor is coupled to G~s~ (stimulatory G-protein), an effect leading to increases in intracellular cyclic adenosine monophosphate (cAMP) levels via activation of adenylate cyclase ([@R60]). We postulated that downstream targets of the β~1~-adrenergic receptor, cyclic-AMP-dependent protein kinase (PKA) regulatory subunit, PKA catalytic subunit, cAMP response element binding protein (CREB) and phosphorylated CREB (pCREB), would show alterations in expression in rat amygdala extracts following early cocaine withdrawal, as well as, following betaxolol treatment during early cocaine withdrawal. Therefore, we tested this hypothesis here. In order to evaluate the activation of PKA, we first performed an extraction procedure in which the nuclear compartment of our amygdalar micro-dissections were separated from cytoplasmic components. Next, we prepared these fractionated extracts for Western blotting, and probed them using antibodies targeted towards the regulatory and/or catalytic subunits of PKA.

To further elucidate gene targets accompanying cell signaling alterations in the amygdala, we focused on CRF gene expression. CRF is implicated in a number of drug abstinence syndromes and relapse to drug-seeking for multiple drugs of abuse, such as marijuana ([@R6]), nicotine ([@R7]), opioids ([@R59]), alcohol ([@R42]) and cocaine ([@R58]; [@R72]; [@R52]). Using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), we examined CRF gene expression in the amygdala of rats during early withdrawal from chronic cocaine administration and following betaxolol treatment. Lastly, implicit to our hypothesis is the localization of β~1~-adrenergic receptor to amygdalar CRF-containing neurons, which has not heretofore been reported. Sections through the forebrain of male Sprague Dawley rats were processed for the dual immunocytochemical detection of β~1~-adrenergic receptor and CRF using confocal fluorescence and electron microscopy.

Materials and Methods {#S2}
=====================

Animal Use and Care {#S3}
-------------------

Adult male Sprague Dawley rats (Harlan, Indianapolis, IN; age ≥ 60 days old, 250--274 g) were used in this study. The animal procedures used were approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University and conform to National Institutes of Health Guide for the Care and Use of Laboratory Animals. Rats were housed two per cage on a 12-h light schedule (lights on at 7:00 am) in a temperature-controlled (20°C) colony room and allowed ad libitum access to food and water. Rats were allowed to acclimate to the facility for 7 days prior to the start of the study. All efforts were made to minimize animal pain and suffering and reduce the number of animals used in these studies.

Drug Treatment {#S4}
--------------

Cocaine hydrochloride (supplied by the National Institute on Drug Abuse, Bethesda, MD) was dissolved in 0.9% sodium chloride (saline) solution at a concentration of 20 mg/ml. For the two day withdrawal experiments, animals were randomly assigned to two treatment groups at the beginning of the study. One half of the animals were administered cocaine once daily at a dosage of 20 mg/kg via intraperitoneal (i.p.) injection for 14 days, while the other half of the animals received once daily i.p. injections of saline solution (1 ml/kg) for 14 days. Subsequent to the 14 day drug administration period, animals were randomly sorted into the four distinct treatment groups based on the treatment they would receive during the 48 hour withdrawal period. The four treatment groups are described in [Table 1](#T1){ref-type="table"}. The 48-hour time period following cessation of chronic cocaine administration has been shown in previous studies to be the point when cocaine withdrawal-related anxiety is at its peak ([@R17]; [@R58]).

As indicated in [Table 1](#T1){ref-type="table"}, two groups of animals received betaxolol hydrochloride (Sigma, St. Louis, MO) dissolved in 0.9 % sodium chloride (5 mg/ml) and two groups received only saline (1 ml/kg) via i.p. injection during the withdrawal period. The first dose of betaxolol was administered 24 hours after the final treatment of chronic cocaine or saline. Another dose of betaxolol was administered at 44 hours following cessation of chronic cocaine administration. Animals were euthanized at the 48 time-point for the purposes of Western blot analysis and/or qRT-PCR experiments. The dose of betaxolol administered (5 mg/kg) was chosen based on dose response studies from our laboratory. This specific dose used in the present study has been shown to be effective in ameliorating cocaine withdrawal-induced anxiety-like behavior in animals ([@R56]).

Protein Extraction {#S5}
------------------

Animals were briefly exposed to isoflurane and then euthanized by decapitation. Brain tissue was rapidly removed on ice from each animal and using a trephine and razor blades, the amygdala brain region (approximately 0.02 g wet weight) was micro-dissected from each (see [Supplemental Figure 1](#SD2){ref-type="supplementary-material"}). The amygdala was homogenized with a pestle and extracted in RadioImmunoPrecipitation Assay (RIPA) lysis buffer (Santa Cruz Biotechnology, Santa Cruz, CA) on ice for 20 min. Lysates were cleared by centrifugation at 13,000 rpm for 12 min at 4 °C.

Nuclear and Cytoplasmic Protein Extraction {#S6}
------------------------------------------

Animals were briefly exposed to isoflurane and then euthanized by decapitation. Brain tissue was rapidly removed on ice from each animal and using a trephine and razor blades, the amygdala brain region (approximately 0.02 g wet weight) was micro-dissected from each. Lysates containing the nuclear and cytoplasmic protein fractions of each sample were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagent kit (Pierce, Rockford, IL) according to manufacturer's instructions.

Western Blotting {#S7}
----------------

Supernatants or protein extracts were diluted with an equal volume of Novex® 2X Tris-Glycine Sodium Dodecyl Sulfate (SDS) sample buffer (Invitrogen, Carlsbad, CA) containing dithiothreitol (DTT; Sigma). Protein concentrations of the undiluted supernatants were quantified using the bicinchoninic acid (BCA) protein assay reagent (Pierce, Rockford, IL). Cell lysates containing equal amounts of protein were separated on 4--12% Tris-Glycine polyacrylamide gels. Whole (un-fractionated) extracts, cytoplasmic extracts and nuclear extracts were loaded onto separate gels at 20 μg, 15 μg and 5 μg per lane, respectively. Next, gels were electrophoretically transferred to Immobilon-P PVDF membranes (Millipore, Bedford, MA). Membranes were incubated in PKA regulatory subunit (1.5 μg/ml; Upstate Cell Signaling Solutions, Lake Placid, NY), PKA catalytic subunits (1 μg/ml, Abcam Inc., Cambridge, MA), pCREB (1:1000; Cell Signaling Technology, Danvers, MA), CREB (2.5 μg/ml; Abcam Inc.) or TATA binding protein (1:2000; Abcam Inc.) primary antibodies (a minimum of two hours) and then alkaline phosphatase conjugated secondary antibodies for 30 minutes in order to probe for the presence of proteins using a Western blotting detection system (Western Breeze Chemiluminescent Kit, Invitrogen). Following incubation in a chemiluminescent substrate (Western Breeze Chemiluminescent Kit, Invitrogen), blots were exposed to X-OMAT AR film (Kodak, Rochester, NY) for different lengths of time to optimize exposures. PKA regulatory subunit, PKA catalytic subunit, pCREB, CREB and TATA binding protein expression were readily detected by immunoblotting in rat amygdala extracts, and each were visualized as a single band that migrated at approximately 52, 42, 43, 43 and 38 kDa, respectively. Blots were incubated in stripping buffer (Restore Stripping Buffer, Pierce) to disrupt previous antibody-antigen interactions and then re-probed with β-actin antibody (1:5000; 1 hour incubation, Sigma) to ensure proper protein loading. The band densities of the western blots were quantified using Un-Scan-It blot analysis software (Silk Scientific Inc., Orem, Utah). PKA regulatory subunit and PKA catalytic subunit immunoreactivity was normalized to β-actin immunoreactivity for each animal. pCREB immunoreactivity was evaluated relative to CREB immunoreactivity for each animal.

Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) {#S8}
----------------------------------------------------------------------

Animals (*n*=6--8 per treatment group; see [Table 1](#T1){ref-type="table"}) were briefly exposed to isoflurane and then euthanized by decapitation. Brain tissue was rapidly removed on ice from each animal and using a trephine and razor blades, the amygdala and frontal cortex brain regions (approximately 0.02 g wet weight) were micro-dissected from each. Total RNA was extracted from these regions using the RNeasy Mini kit (Qiagen Inc., Valencia, CA) according to the manufacturer's recommendations. Residual genomic DNA was digested in these extracts with DNA-free^™^ DNase Treatment (Ambion, Austin, TX) at room temperature for 30 min. RNA extracts were spectrophotometrically quantitated and cDNAs were synthesized from 2 μg of each RNA extract using oligo (dT) primer and the Omniscript® Reverse Transcription kit (Qiagen). Subsequently, cDNAs were stored at −20 °C.

Primer sequences were designed for CRF to contain minimal internal structures (i.e. primer dimers) using the Primer Express software (Applied Biosystems, Foster City, CA). The primer sequences used for CRF were as follows: 5′-GGCCAGGGCAGAGCAGTT (forward) and 5′-GGCCAAGCGCAACATTTC (reverse). The housekeeping gene, glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), was used as an internal control since this gene is constitutively expressed at high levels in most tissues. A QuantiTect Primer Assay was used for amplification of GAPDH (Qiagen).

Thermal cycling, SYBR Green fluorescence detection and data collection was done in a real-time PCR thermal cycler (ABI 7500 Sequence Detection System, Applied Biosystems). Each 25 ul PCR reaction consisted of 1 μl RT product, 1 μM each of forward and reverse CRF primers or 10X GAPDH primer assay (according to manufacturer's instructions) and 12.5 μl SYBR Green (Applied Biosystems). Thermal cycling conditions were 10 min at 95 °C, followed by 40 cycles of 30 s at 95 °C, 30 s at 55 °C and 30 s at 72 °C. A dissociation analysis was performed after the final PCR cycle to verify that nonspecific PCR products were not generated during the PCR run. Additionally, validation experiments using dilutions of untreated sample verified that amplification efficiencies of both CRF and the housekeeping gene were approximately equal.

Data collected by the ABI 7500 Sequence Detection System was expressed as a function of threshold cycle (*C~T~*), which represents the PCR cycle at which an increase in SYBR Green fluorescence above a base line signal can be first detected. Relative quantitative gene expression was calculated with the 2^−ΔΔ^*^C^~T~* method described in [@R36] ([@R36]). For each sample, the *C~T~* for reactions amplifying the gene of interest and the housekeeping gene were determined. The *C~T~* value of CRF for each sample was normalized by subtracting the *C~T~* value of GAPDH (Δ*C~T~*). Saline controls were used as reference samples with mean Δ*C~T~* for the control sample being subtracted from the Δ*C~T~* for all of the other experimental samples (ΔΔ*C~T~*). Lastly, CRF mRNA abundance in experimental groups was calculated relative to CRF mRNA abundance in control samples using the formula 2^−ΔΔ^*^C^~T~*.

Statistical Analysis {#S9}
--------------------

Statistical analysis of the Western blotting data was performed on the normalized densitometry values using one-way ANOVA followed by post-hoc Newman-Keuls Multiple Comparison test. For the qRT-PCR data, average differences in cycle thresholds were analyzed between treatment groups using one-way ANOVA followed by post-hoc Newman-Keuls Multiple Comparison test. Significance for all statistical tests was set at *p*\<0.05.

Immunofluorescent Histochemistry and Confocal Microscopy {#S10}
--------------------------------------------------------

Animals (*n*=5) were deeply anesthetized with sodium pentobarbital (60 mg/kg) and transcardially perfused through the ascending aorta with heparin (1000 units/ml) followed by 4% formaldehyde (Electron Microscopy Sciences, Hatfield, PA) in 0.1 M phosphate buffer (PB, pH 7.4) ([@R71]). The brains were extracted, and 40 μm-thick coronal sections were cut through the rostrocaudal extent of the amygdala (Paxinos and Watson, 1986) using a Vibratome (Technical Product International, St. Louis, MO) and collected into chilled 0.1 M PB.

Tissue sections of the amygdala were incubated in 1% sodium borohydride solution for 30 min to remove reactive aldehydes. They were rinsed in 0.1 M PB and 0.1 M tris--saline buffer (TS; pH 7.6). Sections were then blocked in 0.5% bovine serum albumin (BSA) in 0.1 M TS for 30 min and rinsed extensively in 0.1 M TS. Tissue sections were incubated in a cocktail of rabbit anti-β~1~-adrenergic receptor (1:1000; Oncogene Science, Cambridge, MA) and guinea pig anti-CRF (1:2000; Peninsula Laboratories, Inc., San Carlos, CA) primary antibodies made in 0.1 M TS containing 0.1% BSA at room temperature overnight on a rotary shaker. Subsequently, tissue sections were rinsed in 0.1 M TS and then incubated in a cocktail of fluorescein isothiocyanate donkey anti-rabbit (1:100; Jackson Immunoresearch Laboratories, Inc., West Grove, PA) and rhodamine isothiocyanate donkey anti-guinea pig (1:100; Jackson Immunoresearch Laboratories, Inc.) secondary antibodies made in 0.1 M TS containing 0.1% BSA (3 hrs). Lastly, tissue sections were rinsed in 0.1 M TS and mounted onto gelatinized slides. The sections were air-dried in an enclosure protected from light. Once dry, the slides were dehydrated in a series of alcohols, ending in xylene and coverslipped using DPX (Sigma-Aldrich, St. Louis, MO).

Immunofluorescence labeling was analyzed on the sections using a Zeiss LSM 510 Meta confocal microscope (Oberkochen, Germany). Images of fluorescent labeling of the sections were captured and dual fluorescence merged images were generated by the confocal microscope.

Immunoelectron Microscopy and Electron Microscopy {#S11}
-------------------------------------------------

Rats (*n*=5) were deeply anesthetized with sodium pentobarbital (60 mg/kg) and perfused transcardially through the ascending aorta with 10 ml heparinized saline followed by 50 ml of 3.75% acrolein (Electron Microscopy Sciences), and 200 ml of 2% formaldehyde (Electron Microscopy Sciences) in 0.1 M PB (pH 7.4). The brains were immediately removed and sectioned into 1--3 mm coronal slices. The slices were post-fixed for 30 min and 40 μm-thick sections were cut through the rostrocaudal extent of the amygdala using a Vibratome and collected into chilled 0.1 M PB. Forty-μm thick sections through the rostrocaudal extent of the amygdala were processed for electron microscopic analysis of β~1~-adrenergic receptor and CRF in the same sections and were processed following the same protocol described above for immunofluorescent histochemistry until the point of the secondary antibody incubation.

Tissue sections were incubated in a primary antibody cocktail of rabbit anti-β~1~-adrenergic receptor (1:1000; Oncogene Science, Cambridge, MA) and guinea pig anti-CRF (1:2000; Peninsula Laboratories, Inc.) for 15--18 h at room temperature. The following day, tissue sections were rinsed three times in 0.1 M TS, incubated in biotinylated donkey anti-rabbit (1:400; Jackson Immunoresearch Laboratories, Inc.) and biotinylated donkey anti-guinea pig (1:400; Jackson Immunoresearch Laboratories, Inc.) for 30 min, and then rinsed again in 0.1 M TS. Next, sections underwent a 30 min incubation in an avidin-biotin complex (Vector Laboratories, Burlingame, CA). CRF immunoreactivity was visualized by a 6 min reaction in 22 mg of 3,3′-diaminobenzidine (Sigma-Aldrich Inc., St. Louis, MO) and 10 μl of 30% hydrogen peroxide in 100 ml of 0.1 M TS. Sections were continuously agitated with a rotary shaker during all aforementioned incubations and washes.

For gold-silver localization of β~1~-adrenergic receptor, sections were rinsed three times with 0.1 M TS, followed by rinses with 0.1 M PB and 0.01 M phosphate buffered saline (PBS; pH 7.4). Sections were then incubated in a 0.2% gelatin-PBS and 0.8% BSA buffer for 10 min. Subsequently, sections were incubated in 1nm gold anti-rabbit antibody (1:50; Amersham Biosciences, Piscataway, NJ, USA) at room temperature for 2 hours. Next, sections were rinsed in 0.2% gelatin-PBS and 0.8% BSA buffer and followed by a rinse in 0.01 M PBS. Sections were then incubated in 2% glutaraldehyde (Electron Microscopy Sciences) in 0.01 M PBS for 10 min followed by washes in 0.01 M PBS and 0.2 M sodium citrate buffer (pH 7.4). A silver enhancement kit (Amersham Biosciences) was used for silver intensification of the gold particles. The optimal times for silver enhancement time were determined by empirical observation but ranged from 12--15 min. Following silver intensification, tissue sections were rinsed in 0.2 M citrate buffer and 0.1 M PB, incubated in 2% osmium tetroxide (Electron Microscopy Sciences) in 0.1 M PB for 1 h, washed in 0.1 M PB, dehydrated in an ascending series of ethanol followed by propylene oxide and flat embedded in Epon 812 (Electron Microscopy Sciences) ([@R33]; [@R70]).

Flat embedded tissue sections were mounted onto Epon capsules and thin sections approximately 50--100 nm in thickness were cut with a diamond knife (Diatome-US, Fort Washington, PA, USA) using a Leica Ultracut (Leica Microsystems, Wetzlar, Germany). Sections were collected on copper mesh grids and examined with a Hitachi electron microscope. Digital electron micrographic images were collected and figures were assembled using Adobe Photoshop.

The cellular elements (cell bodies, dendrites, axon terminals) were identified based on the description of Peters and colleagues ([@R50]). A terminal was considered to form a synapse if it showed synaptic vesicles near a restricted zone of parallel membranes with slight enlargement of the intercellular space, and/or associated with postsynaptic thickening. Asymmetric synapses were identified by thick postsynaptic densities (Gray's type I) ([@R15]), in contrast, symmetric synapses had thin densities (Gray's type II) ([@R15]) both pre-and postsynaptically. A non-synaptic apposition was defined as an axon terminal plasma membrane juxtaposed to that of a dendrite or soma devoid of recognizable membrane specializations and no intervening glial processes.

Results {#S12}
=======

Betaxolol blocks cocaine withdrawal-induced increases in amygdalar PKA regulatory subunit expression {#S13}
----------------------------------------------------------------------------------------------------

A one-way ANOVA analysis demonstrated a significant difference among treatment groups (see [Table 1](#T1){ref-type="table"}; *n*=5/treatment group) in PKA regulatory subunit expression by western blot analysis \[*p*=0.0284, *F*(3,16)=3.916\] and post-hoc comparison tests among these groups revealed the differences. In [Figure 1](#F1){ref-type="fig"}, amygdalar PKA regulatory subunit immunoreactivity of the groups of animals is expressed as a percentage of the control mean when the control equals 100 (±S.E.M.). Amygdala extracts from animals undergoing cocaine withdrawal with no betaxolol treatment (CS) exhibited a significant increase (*p*\<0.05) in PKA regulatory subunit protein expression compared to saline control animals (SS). Likewise, PKA regulatory subunit immunoreactivity was significantly greater (*p*\<0.05) in cocaine withdrawn animals (CS) compared to animals treated with chronic saline followed by betaxolol treatment (SB). However, there was no significant difference (*p*\>0.05) in PKA regulatory subunit protein expression levels between animals treated with chronic saline and no betaxolol (SS) and animals treated with chronic saline followed by betaxolol treatment (SB). Betaxolol administration had a significant effect on PKA regulatory subunit expression in the amygdala of animals that underwent cocaine withdrawal (CB), as amygdala extracts from those animals displayed a significant decrease (*p*\<0.05) in PKA regulatory subunit expression compared to cocaine administered animals that did not receive betaxolol treatment during withdrawal (CS). Also of importance, amygdala extracts from animals treated with betaxolol during cocaine withdrawal (CB) exhibited similar levels of PKA regulatory subunit protein expression as animals treated with chronic saline and no betaxolol treatment (SS; *p*\>0.05), and also animals treated with chronic saline followed by betaxolol treatment (SB; *p*\>0.05). Statistical significance is indicated on graph; \* *p*\<0.05 ([Figure 1](#F1){ref-type="fig"}).

Betaxolol reverses cocaine withdrawal-induced alterations in PKA catalytic subunit expression in amygdalar cytoplasmic and nuclear extracts {#S14}
-------------------------------------------------------------------------------------------------------------------------------------------

By ANOVA analysis, there was a significant difference among treatment groups (see [Table 1](#T1){ref-type="table"}; *n*=5/treatment group) in PKA catalytic subunit expression in both cytoplasmic \[*p*=0.0085; *F*(3,16)=5.523\] and nuclear \[*p*=0.0166; *F*(3,16)=4.601\] amygdalar extracts. PKA catalytic subunit immunoreactivity in both the cytoplasmic and nuclear amygdalar extracts was plotted as a percentage of the control mean when the control equals 100 (±S.E.M.; [Figure 2](#F2){ref-type="fig"}). Amygdala cytoplasmic extracts from animals undergoing cocaine withdrawal with no betaxolol treatment (CS) exhibited a significant decrease (*p*\<0.05) in PKA catalytic subunit protein expression compared to saline control animals (SS; bottom left). Alternatively, PKA catalytic subunit expression was significantly elevated (*p*\<0.05) in nuclear extracts from CS animals compared to controls (SS; bottom right), indicating the likely translocation of PKA catalytic subunit from the cytoplasm to the nuclear compartment during early cocaine withdrawal. Cytoplasmic and nuclear amygdalar extracts from animals receiving betaxolol administration during cocaine withdrawal (CB; both left and right bottom) demonstrated a reversal of these alterations in PKA catalytic subunit protein levels. Hence, following betaxolol treatment (CB), PKA catalytic subunit expression was returned to levels comparable to those of control animals (SS) in both cytoplasmic and nuclear amygdalar extracts. Statistical significance between groups of animals is indicated on graphs; \* *p*\<0.05, \*\* *p*\<0.01 ([Figure 2](#F2){ref-type="fig"}).

Critical to the significance of the alterations in expression of PKA catalytic subunit that we demonstrated in these studies was the precision of the nuclear and cytoplasmic extraction procedure. In order to confirm that our extracts contained only the nuclear or cytoplasmic cellular fractions as desired, we probed blots containing these extracts with an antibody targeted towards TATA Binding protein. TATA Binding protein is a DNA binding protein that binds specifically to the TATA box found in gene promoters, and is vital to the initiation of all eukaryotic transcription ([@R44]). Hence, TATA Binding protein makes a useful loading control for nuclear extracts ([@R32]). TATA Binding protein immunoreactivity was detected in nuclear extracts from all treatment groups ([Figure 2](#F2){ref-type="fig"}).

Betaxolol blocks cocaine withdrawal-induced increases in CREB phosphorylation in amygdalar nuclear extracts {#S15}
-----------------------------------------------------------------------------------------------------------

A significant difference was found between groups (see [Table 1](#T1){ref-type="table"}, *n*=5/treatment group) in CREB phosphorylation in amygdalar nuclear extracts \[*p*=0.0354, *F*(3,16)=3.650\]. pCREB protein densitometry levels were evaluated relative to CREB densitometry levels for each animal. pCREB/CREB immunoreactivity in the amygdala of these animals was plotted as a percentage of the control mean when the control equals 100 (±S.E.M.; [Figure 3](#F3){ref-type="fig"}). Amygdala extracts from animals undergoing cocaine withdrawal with no betaxolol treatment (CS) exhibited a significant increase (*p*\<0.05) in CREB phosphorylation compared to saline control animals (SS). Likewise, pCREB immunoreactivity was significantly greater (*p*\<0.05) in cocaine withdrawn animals (CS) compared to animals treated with chronic saline followed by betaxolol treatment (SB). There was no significant difference (*p*\>0.05) in pCREB protein levels between animals treated with chronic saline and no betaxolol (SS) and animals treated with chronic saline followed by betaxolol treatment (SB). Amygdala extracts from animals that were administered betaxolol during cocaine withdrawal (CB) displayed a significant decrease (*p*\<0.05) in CREB phosphorylation compared to cocaine administered animals that did not receive betaxolol treatment during withdrawal (CS). Amygdala extracts from CB animals exhibited similar levels of pCREB protein as saline control animals (SS; *p*\>0.05), and also animals treated with chronic saline followed by betaxolol treatment (SB; *p*\>0.05).

TATA binding protein (BP) immunoreactivity was used as a nuclear loading control in these experiments. Cytoplasmic extracts lack immunoreactivity for TATA BP, while nuclear extracts demonstrate TATA BP immunoreactivity ([Figure 3](#F3){ref-type="fig"}).

Betaxolol attenuates cocaine withdrawal-induced increases in amygdalar CRF mRNA levels {#S16}
--------------------------------------------------------------------------------------

Data from the RT-PCR experiments was analyzed by the comparative *C~T~* method using the formula 2^−ΔΔ^*^C^~T~*. Fold change differences in CRF mRNA abundance in the three drug treatment groups (CS, SB and CB; see [Table 1](#T1){ref-type="table"}) were plotted relative to saline control (SS) when the saline control group equals 1 ([Figure 4](#F4){ref-type="fig"}). Comparison of average threshold cycles for CRF between the treatment groups using one-way ANOVA revealed a significant difference in CRF mRNA expression between the groups \[see [Table 1](#T1){ref-type="table"}; *p*=0.0156, *F*(3,22)=4.306\] and post-hoc Newman-Keuls Multiple Comparison test detailed these differences. Confirming reports of others ([@R74]), our data demonstrated that CRF mRNA expression was significantly upregulated in amygdalar extracts from animals following early cocaine withdrawal ([Figure 4](#F4){ref-type="fig"}, CS vs. SS; *p*\<0.05). However, this increase was blocked in amygdalar extracts from animals that were treated with betaxolol following cocaine administration (CB vs. CS, *p*\<0.05). Betaxolol treatment alone did not have any significant effect on amygdalar CRF mRNA expression (SB vs. SS; *p*\>0.05). Using qRT-PCR, we also examined CRF mRNA expression levels in frontal cortex micro-dissections that we extracted from animals from the four drug treatment groups (see [Table 1](#T1){ref-type="table"}). From these experiments, we found no statistically significant difference in CRF mRNA expression levels in frontal cortex extracts among these groups (data not shown). Collectively, the Western blotting and qRT-PCR data from the present study suggest that betaxolol treatment during cocaine withdrawal may block increases in amygdalar CRF gene expression by attenuating an amygdalar β~1~-adrenergic receptor-mediated cell signaling pathway (see [Figure 5](#F5){ref-type="fig"}).

β~1~-adrenergic receptors are located on numerous CRF-containing neurons of the CNA {#S17}
-----------------------------------------------------------------------------------

β~1~-adrenergic receptors were frequently observed on CRF-containing neurons of the central nucleus of the amygdala (CNA) and this observation was made using both confocal and electron microscopy. For immunofluorescent confocal microscopy, rat brain tissue sections containing the amygdala were labeled for CRF using rhodamine isothiocyanate-conjugated secondary antibody, while β~1~-adrenergic receptors were labeled using fluorescein isothiocyanate-conjugated secondary antibody. Using confocal microscopy, CRF immunoreactivity was characterized as a diffuse red fluorescent product and was localized to cell bodies ([Figure 6, A and D](#F6){ref-type="fig"}; thick white arrows), whereas β~1~-adrenergic receptor immunoreactivity was visualized as a punctate green fluorescent label also localized to perikarya ([Figure 6, B and E](#F6){ref-type="fig"}; thick white arrows). When the fluorescent images were merged, dual labeling for both CRF and β~1~-adrenergic receptor was identified as a yellow fluorescent label ([Figure 6, C and F](#F6){ref-type="fig"}; thick white arrows). Not all CRF-labeled cells in the CNA contained labeling for β~1~-adrenergic receptor ([Figure 6, A, C, D and F](#F6){ref-type="fig"}; thin white arrows) and we also observed some β~1~-adrenergic receptor labeling not on CRF neurons.

Using electron microscopy, we observed ultrastructural evidence for co-localization of β~1~-adrenergic receptors and CRF in the amygdala. CRF immunoreactivity was identified by an electron-dense peroxidase reaction product and β~1~-adrenergic receptor immunoreactivity was visualized as immunogold-silver particles. A profile was considered to be positive for immunogold particle labeling only if three or more immunogold particles were present in the same profile. CRF and β~1~-adrenergic receptor immunoreactivities were sometimes observed in separate dendrites in the same neuropil ([Figure 7, A](#F7){ref-type="fig"}), but were often observed co-localized in the same dendrites of the CNA ([Figure 7, B and C](#F7){ref-type="fig"}). We quantified the frequency of co-localization and found that of the profiles exhibiting immunoreactivity for β~1~-adrenergic receptor (*n*=474), 45% of these profiles also contained CRF labeling. Furthermore, of the profiles exhibiting CRF immunoreactivity (*n*=389), 55% of these profiles also contained β~1~-adrenergic receptor immunoreactivity. We also observed that dendrites of co-localized CRF and β~1~-adrenergic receptors form both asymmetric (curved arrows) and symmetric (double arrows) synapses with axon terminals ([Figure 7, B and C](#F7){ref-type="fig"}).

By electron microcopy, we also investigated the distribution of β~1~-adrenergic receptors in CRF-immunoreactive dendritic processes in the amygdala. β~1~-Adrenergic receptors were found located within the cytoplasmic compartment and also distributed along the plasma membrane of CRF-immunoreactive dendrites ([Figure 8](#F8){ref-type="fig"}). We quantified the frequency of localization of β~1~-adrenergic receptor labeling either on the plasma membrane versus within the cytoplasm of CRF-labeled profiles and determined that 62.3% of our dual CRF and β~1~-adrenergic receptor -labeled profiles exhibited β~1~-adrenergic receptor labeling on the plasma membrane, while 37.7% of these profiles demonstrated β~1~-adrenergic receptor labeling within the cytoplasm.

Discussion {#S18}
==========

Our previous studies demonstrated increased amygdalar β~1~-adrenergic receptor expression during early cocaine withdrawal ([@R56]). The present study extends these previous results by showing that alterations in amygdalar cell signaling and amygdalar CRF gene expression accompany these alterations. We further demonstrate that treatment with betaxolol, a selective β~1~-adrenergic receptor antagonist ([@R45]), during early cocaine withdrawal (2 days) blocks increases in a β~1~-adrenergic receptor-mediated cell signaling pathway and CRF gene expression. These data suggest a potential cellular mechanism underlying the efficacy of betaxolol in the treatment of cocaine withdrawal. These findings could have important implications in the pursuit of potential pharmacotherapies for the treatment of withdrawal-induced anxiety following cocaine addiction.

Early periods of withdrawal from chronic cocaine administration are accompanied by significant anxiety-like behavior ([@R17]; [@R58]; [@R56]). This behavior has been attributed, in part, to increases in both amygdalar CRF gene expression ([@R58]; [@R74]) and β~1~-adrenergic receptor expression ([@R56]). The hypothesis that β~1~-adrenergic receptors localized to amygdalar CRF neurons play an important role in withdrawal-induced anxiety is emerging as it has already been established that norepinephrine and CRF systems interact in the brain to modulate stress responses ([@R68]; [@R67]; [@R35]; [@R25]; [@R69]).

Activation of β~1~-adrenergic receptors stimulates G~s~, and this, in turn, results in an increase in intracellular cAMP levels ([@R60]) (see [Figure 5](#F5){ref-type="fig"}). Accumulation of intracellular cAMP ([@R43]) results in PKA activation, whereby, the binding of cAMP causes PKA regulatory subunits to alter their conformation, and the catalytic subunits to dissociate from the complex ([@R14]; [@R13]; [@R1]). The catalytic subunits translocate into the nucleus to phosphorylate specific substrate protein molecules, such as CREB, while the regulatory subunits remain in the cytoplasm ([@R14]; [@R13]; [@R64]; [@R53]; [@R1]).

Our results showing an increase in PKA catalytic subunit expression in nuclear amygdalar extracts and a simultaneous decrease in PKA catalytic subunit expression in cytoplasmic amygdalar extracts from rats following cocaine withdrawal suggest a translocation of the PKA catalytic subunits to the nucleus. This translocation indicates PKA activation ([@R2]). Interestingly, the expression of PKA regulatory subunit was significantly increased in whole amygdalar extracts during this time period also. The alteration in PKA we observed was accompanied by a significant increase in CREB phosphorylation in amygdalar nuclear extracts, while overall CREB levels remained unchanged. Our finding demonstrating increases in CREB phosphorylation further supports activated PKA in our cocaine withdrawn animals, as phosphorylation of CREB at Ser-133 occurs in response to PKA activation ([@R43]; [@R40]; [@R22]).

Activation of PKA within the amygdala is thought to contribute to the synaptic plasticity and reward-related learning that underlies pathologic behavior in drug addicted individuals ([@R54]; [@R3]; [@R21]). Jentsch et al. demonstrated that intra-amygdalar infusions of Sp-cAMP, which activates PKA, in rats produces concentration-dependent enhancements of the acquisition of approach to a conditioned stimulus that predicts water availability ([@R21]). A similar effect was produced in animals using intra-amygdalar infusion of cholera toxin, which elevates cAMP levels. On the contrary, intra-amygdalar infusions of Rp-cAMPS, an inhibitor of PKA, impaired acquisition of approach behavior ([@R21]). Modulation of PKA activation in other brain regions, such as the nucleus accumbens, has also been specifically associated with cocaine self-administration ([@R63]) and motivation to obtain cocaine ([@R37]). In rats self administering cocaine under a fixed ratio 1 schedule (each response produces an infusion of cocaine), activation of PKA in the nucleus accumbens produced increases in levels of cocaine intake whereas, inhibition produced a decrease in total intake ([@R63]). After extinction from cocaine self-administration, infusions of Sp-cAMPS into the nucleus accumbens induced generalized responding at both drug-paired and inactive levers and increased phosphorylation of CREB ([@R63]). In another study, bilateral infusions of Sp-cAMPS resulted in an increase in progressive ratio responding for cocaine, whereas infusions of Rp-cAMPS produced persistent decreases in progressive-ratio responding ([@R37]).

Data from the aforementioned studies suggest that PKA activation may be involved in the incentive and motivational aspects of drug addiction, which could contribute to compulsive drug seeking behavior ([@R55]; [@R54]; [@R21]). It is plausible then that the activation of PKA that we observed in the amygdala during early cocaine abstinence may have multiple consequences. Our data add to this growing literature and suggests that this activation may serve as a molecular substrate for the cocaine withdrawal-related anxiety that occurs during this time period. This conjecture is supported by observation of a concomitant significant increase in amygdalar CRF gene expression during early withdrawal, a result previously described by others ([@R74]), but whose mechanism was unknown. Therefore, it is tempting to speculate that the alterations in cell signaling that we observed during this time period contribute to increased CRF gene expression.

Elevations in CREB phosphorylation have also been observed in the brain after exposure to various stressors, including forced-swim and restraint stress ([@R31]) and are thought to be involved in cocaine-induced drug reinstatement ([@R30]). PKA, pCREB and cAMP-dependent CRE-mediated transcription have also been specifically implicated in alcoholism ([@R66]; [@R47]; [@R48]). Alcohol-preferring rats, which exhibit increased ethanol consumption, express lower levels of CREB and pCREB in the CNA and medial amygdala (MeA), but not in the basolateral nucleus of the amygdala (BLA) compared to non-preferring rats ([@R48]). It is thought that these alcohol-preferring rats voluntarily drink excessive amounts of alcohol to reduce high anxiety levels that occur in these animals during this time ([@R48]). This concept is further supported by evidence demonstrating that ethanol intake reduced higher anxiety levels in alcohol-preferring rats and also increased CREB function in these animals ([@R48]). More recent studies have shown that ethanol withdrawal-induced anxiety in rats is accompanied by decreased CREB phosphorylation, as well as decreased activation of other cell signaling elements, in the CNA and MeA, but not in the BLA ([@R49]).

The findings of the aforementioned alcohol studies are contrary to our studies that demonstrate increased expression of anxiety-like behavior in animals during cocaine withdrawal ([@R56]) coincident with increased CREB phosphorylation in the amygdala. However, while the immunofluorescent and electron microscopy experiments were focused largely on evaluating β~1~-adrenergic receptor immunoreactivity in relation to CRF immunoreactivity in the CNA, a limitation of our present study is that the Western blotting and RT-PCR experiments were performed on amygdalar extracts containing the CNA, as well as, other nuclei of the amygdala. Given the cellular alterations that we have observed in the whole amygdala micro-dissections, and the divergent alterations in CREB activation that we have observed compared to previous studies in alcohol addiction, future experiments will be aimed at evaluating potential alterations in CREB activation in the individual amygdalar nuclei. However, we speculate that the cellular changes we observed in the present study are likely a reflection of changes occurring in the CRF-rich CNA specifically since previous studies demonstrate that the CNA is implicated in mediating cocaine withdrawal symptomatology, such as anxiety ([@R38]; [@R74]), and is also associated with mediating stress-induced reinstatement of cocaine seeking in rats ([@R10]; [@R34]; [@R41]). Nevertheless, chronic cocaine self-administration upregulates norepinephrine transporter in the BLA in animals ([@R4]) and so, it is also plausible that regions such as the BLA underlie the noradrenergic receptor-mediated cellular alterations that we observed. Furthermore, the BLA, thought to be fundamental in the formation and preservation of emotional memories, has been implicated in mediating cue-induced relapse to both major drugs of abuse, such as cocaine ([@R11]; [@R62]) and heroin ([@R19]).

Our findings showing increased CREB phosphorylation during early phases of withdrawal are interesting in light of previous studies that have demonstrated an association between increased pCREB and increased CRF gene activation ([@R28]; [@R29]; [@R73]). When CREB is phosphorylated, it functions to stimulate transcription in genes that contain the cAMP response element (CRE) in their promoter regions ([@R64]; [@R40]). It has been established that the CRF gene contains a CRE element in the promoter region and CRF gene transcription is regulated by changes in both cAMP concentration and CRE binding ([@R61]; [@R20]; [@R18]). Although indirect, our data suggest a potentially upregulated signaling pathway that may culminate in increased CRF gene transcription leading to the behavioral manifestation of anxiety.

In the present study, we demonstrate that treatment with betaxolol during early cocaine withdrawal reverses the alterations in intracellular messenger expression (PKA regulatory subunit, PKA catalytic subunit and pCREB) that accompany elevations in β~1~-adrenergic receptors during this time period, as well as returned CRF mRNA levels to that of control animals. Activation of CRF neurotransmission in the amygdala is thought to mediate the anxiety and stress-like symptoms that characterize drug withdrawal syndromes ([@R58]; [@R57]; [@R25]; [@R52]). This effect may be mediated by not only local CRF signaling within the amygdala, but also by the activation of CRF projections to other brain regions which mediate anxiety and stress such as, the bed nucleus of the stria terminalis ([@R25]; [@R27]; [@R5]) and the noradrenergic locus coeruleus ([@R27]; [@R69]; [@R9]).

The proposed mechanism underlying the efficacy of betaxolol treatment is supported by our anatomical data showing localization of β~1~-adrenergic receptors to CRF-containing neurons in the amygdala. Our anatomical studies indicate that β~1~-adrenergic receptors are frequently localized to amygdalar cells containing CRF, in that, more than half of CRF-labeled neurons in the amygdala also express labeling for β~1~-adrenergic receptor. While our experiments demonstrated that β~1~-adrenergic receptors were distributed both on the plasma membrane and/or in the cytoplasm of CRF-labeled neurons, we found β~1~-adrenergic receptors to be primarily localized to the plasma membrane of those neurons. This finding suggests that the majority of β~1~-adrenergic receptors on CRF neurons may be available for ligand binding, and hence, emphasizes the potential importance of this anatomical substrate in the modulation of CRF gene expression by modulation of β~1~-adrenergic receptors. Moreover, dendrites of co-localized CRF and β~1~-adrenergic receptors form both asymmetric and symmetric synapses with axon terminals, an indication that these synapses may be either excitatory or inhibitory in nature. Together, this compelling data further supports the hypothesis that the cellular interactions between β~1~-adrenergic receptors and CRF in the amygdala may serve as an important circuit involved in the induction of anxiety following cessation of chronic cocaine use.

Studies from our laboratory and others have shown that early cocaine withdrawal in rats is characterized by the behavioral manifestation of anxiety ([@R56]) and also by the augmentation of amygdalar CRF gene expression ([@R74]). Our data support that these effects are likely linked to increases in amygdalar β~1~-adrenergic receptor expression that occurs during this time period. Nonetheless, it has not yet been determined whether treatment with a β~1~-adrenergic receptor agonist can mimic the effects of cocaine withdrawal, either by the precipitation of anxiety-like behavior or by elevating CRF gene expression. Hence, this type of study may indeed be a fruitful avenue to pursue in order to further elucidate the cellular mechanism underlying the role of β~1~-adrenergic receptors in cocaine withdrawal-related anxiety.

In conclusion, the findings contained in the present study may have pharmacotherapeutic implications, as blocking amygdalar β~1~-adrenergic receptors may be a clinically effective means of modulating the activation of CRF neuronal mechanisms that likely prompt negative symptomatology during early phases of drug withdrawal. Betaxolol is an FDA approved drug (brand name: Kerlone) currently used in clinical settings to treat glaucoma ([@R16]; [@R45]), hypertension ([@R39]) and specific coronary dysfunctions ([@R24]). Betaxolol, is classified as highly selective for β~1~-adrenegic receptors ([@R45]), readily crosses the blood brain barrier ([@R65]), and has no partial agonist activity ([@R45]). Other β~1~--adrenergic receptor antagonists such as, metoprolol, atenolol, esmolol, and acebutolol were considered for use in the present study, but were disregarded because these agents either had limited ability to penetrate the brain, had some intrinsic sympathomimetic activity or had a very short duration of action ([@R16]).

Propranolol (brand name: Inderal), a non-selective beta-adrenergic receptor antagonist, used to treat hypertension, has demonstrated efficacy in blocking cocaine withdrawal-induced anxiety in rats during early abstinence (2 days) from chronic cocaine administration (20 mg/kg/day, 14 days) ([@R17]) and, in clinical studies, has shown some promising effects in individuals with more severe cocaine withdrawal symptoms ([@R23]). Our previous studies ([@R56]) demonstrate that no significant alteration in amygdalar β~2~-adrenergic receptor expression occurs during cocaine withdrawal in rats, alas, propanolol may not be the most ideal treatment for cocaine withdrawal-related anxiety, as propanolol blocks both β~1~- and β~2~- adrenergic receptors. β~2~-adrenergic receptors, similar to β~1~-adrenergic receptors, are G~s~-protein-coupled receptors and both function to increase cAMP. However, at present, there is no evidence in the literature that these two receptors regulate expression of the exact same genes. More specifically, the present study demonstrates that treatment with betaxolol during cocaine withdrawal blocks increases in amygdalar CRF gene expression; an effect that we hypothesize may underlie its efficacy in ameliorating withdrawal-related anxiety. Propanolol may also potentially affect amygdalar CRF gene expression, as it blocks both β~1~- and β~2~-adrenergic receptors, however, it is unknown at this time if this molecular alteration could underlie the partial efficacy of propanolol in treating cocaine withdrawal symptomatology. It is also conceivable that propanolol has not met with full success in treating cocaine withdrawal symptoms, since propanolol, by unnecessarily blocking β~2~-adrenergic receptors that have not been altered by the drug withdrawal, could possibly elicit counter-productive effects (e.g. disturb the regulation of other genes). Collectively, the preclinical and clinical studies described above are supportive of the potential pharmacotherapeutic value of betaxolol in the treatment of cocaine withdrawal-related anxiety. However, future studies are warranted to further characterize the biological underpinnings of amygdalar involvement in withdrawal-induced anxiety, as well as examine the effect of direct intracranial β~1~-adrenergic receptor blockade on amygdalar CRF peptide expression and CRF release in this important limbic region.
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CRF

:   corticotropin-releasing factor

qRT-PCR

:   quantitative reverse transcriptase-polymerase chain reaction

cAMP

:   cyclic adenosine monophosphate

PKA

:   cyclic-AMP-dependent protein kinase

CREB

:   cAMP response element binding protein

pCREB

:   phosphorylated CREB

CNA

:   central nucleus of the amygdala

PB

:   phosphate buffer

TS

:   tris-saline buffer

BSA

:   bovine serum albumin

PBS

:   phosphate buffered saline

GAPDH

:   glyceraldehyde-3-phosphate-dehydrogenase

BLA

:   basolateral nucleus of the amygdala

![Western blots demonstrating PKA Regulatory Subunit immunoreactivity in the amygdala of animals from four different drug treatment groups (see [Table 1](#T1){ref-type="table"}). PKA Regulatory Subunit immunoreactivity in the amygdala of these animals is expressed as a percentage of the control mean when the control equals 100 (±S.E.M.). PKA regulatory subunit expression is elevated in the amygdala following early cocaine withdrawal, however; this effect is reversed following betaxolol treatment during cocaine withdrawal. Statistical significance between groups of animals is indicated on graph; \* *p*\<0.05.](nihms349520f1){#F1}

![Western blots demonstrating PKA Catalytic Subunit and the nuclear localization marker, TATA Binding Protein (BP), expression in cytoplasmic (top left) and nuclear (top right) amygdalar extracts obtained from four different groups of drug treated animals (see [Table 1](#T1){ref-type="table"}). In both the cytoplasmic and nuclear extracts, PKA Catalytic Subunit immunoreactivity in the amygdala of these animals is expressed as a percentage of the control mean when the control equals 100 (±S.E.M.). PKA catalytic subunit expression was significantly decreased in amygdalar cytoplasmic extracts and concurrently increased significantly in amygdalar nuclear extracts from animals that underwent cocaine withdrawal. Betaxolol administration during early cocaine withdrawal reversed alterations in PKA catalytic subunit expression in amygdalar cytoplasmic and nuclear extracts to control levels. Statistical significance between groups of animals is indicated on graphs; \* *p*\<0.05, \*\* *p*\<0.01. TATA BP immunoreactivity was used as a nuclear loading control. Cytoplasmic extracts lack immunoreactivity for TATA BP, while nuclear extracts demonstrate TATA BP immunoreactivity. β-actin immunoreactivity was evaluated in cytoplasmic amygdalar extracts (top left) as a loading control.](nihms349520f2){#F2}

![Western blots demonstrating pCREB, CREB, and the nuclear localization marker, TATA BP, immunoreactivity in the amygdala of animals from four different drug treatment groups (see [Table 1](#T1){ref-type="table"}). pCREB protein densitometry levels were evaluated relative to CREB protein densitometry levels for each animal. pCREB/CREB immunoreactivity in the amygdala of these animals is expressed as a percentage of the control mean when the control equals 100 (±S.E.M.). CREB phosphorylation is increased in amygdalar nuclear extracts following early cocaine withdrawal, however; betaxolol administration during early cocaine withdrawal blocks this increase. Statistical significance between groups of animals is indicated on graph; \* *p*\<0.05.](nihms349520f3){#F3}

![Effect of betaxolol treatment during cocaine withdrawal on CRF mRNA levels in the amygdala. Quantitative RT-PCR data was analyzed by the comparative *C~T~* method using the formula 2^−ΔΔ^*^C^~T~*. Fold change differences in CRF mRNA abundance in the three drug treatment groups (CS, SB and CB; see [Table 1](#T1){ref-type="table"}) are plotted relative to saline control (SS) when the saline control group equals 1. CRF mRNA expression was significantly increased in amygdalar extracts from animals following early cocaine withdrawal (CS vs. SS); however, this increase was attenuated in amygdalar extracts from animals that were treated with betaxolol following cocaine administration (CB vs. CS). Betaxolol treatment alone did not have any significant effect on amygdalar CRF mRNA expression (SB vs. SS). Statistical significance between groups of animals is indicated on graph; \* *p*\<0.05.](nihms349520f4){#F4}

![Proposed cell signaling pathway of noradrenergic influence on CRF transcription. Norepinephrine (NE) in the extracellular space binds to a G-protein coupled adrenergic receptor spanning the neuronal cell membrane (1). This ligand-receptor complex then activates the G protein, causing the alpha subunit to dissociate from the beta and gamma subunits (2). The activated alpha subunit of the G protein functions to activate the plasma membrane bound enzyme, adenylyl cyclase (3). Adenylyl cyclase synthesizes cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP) (4). cAMP binds to the regulatory subunits of cycle-AMP-dependent protein kinase (PKA) (5). This induces a conformational change causing the regulatory subunits to release the catalytic subunits, thereby activating the kinase activity of the catalytic subunits (6). Once the catalytic subunits are freed and active, they translocate into the nucleus of the cell to phosphorylate cAMP response element binding protein (CREB) (7). The regulatory subunits remain in the cytoplasm. Phosphorylated CREB (pCREB) then recruits a transcriptional co-activator called CREB-binding protein (CBP) (8). CBP recognizes the regulatory region of the target gene called the cAMP response element (CRE) and stimulates gene transcription (9). The culmination of this proposed cell signaling pathway is the transcription of CRF (10).](nihms349520f5){#F5}

![β~1~-adrenergic receptors are located on CRF-containing neurons of the amygdala. A and D: High magnification confocal photomicrographs of two separate coronal sections through the CNA labeled for CRF using rhodamine isothiocyanate-conjugated secondary antibody; thin arrows point to CRF-immunoreactive cells, while thick arrows indicate CRF-immunoreactive perikarya containing β~1~-adrenergic receptors (see panels C and F). B and E: The same coronal sections as shown in figures A and D, respectively, labeled for β~1~-adrenergic receptors (β1-AR) using fluorescein isothiocyanate-conjugated secondary antibody; thick arrows indicate CRF-immunoreactive perikarya containing β~1~-adrenergic receptors (β1-AR) (see panels C and F). C and F: Merged images of panels A and B and D and E, respectively. Thick arrows show immunoreactivity for CRF and β~1~-adrenergic receptors, while thin arrows indicate single-labeling for CRF only.](nihms349520f6){#F6}

![Ultrastructural evidence for co-localization of β~1~-adrenergic receptors and CRF in the amygdala. A: Electron photomicrograph showing a dendrite containing immunogold-silver labeling (arrowheads) for β~1~-adrenergic receptor (β1-AR). A dendrite containing peroxidase labeling (arrows) for CRF (CRF-d) can also be identified in the neuropil. Scale bar: 0.50 μm. B--C: Electron photomicrographs showing CRF (CRF-d; immunoperoxidase) and β~1~-adrenergic receptors (β1-AR; immunogold) immunoreactivities co-localized in dendrites of the CNA. Arrowheads indicate immunogold particles for β~1~-adrenergic receptors (β1-AR) and peroxidase labeling for CRF (CRF-d; arrows) is identified as electron-dense reaction product. Dendrites of co-localized CRF and β~1~-adrenergic receptors form asymmetric (curved arrows) and symmetric (double arrows) synapses with axon terminals. Scale bars: 0.50 μm. Abbreviations: m, mitochondria; ut, unlabeled terminal.](nihms349520f7){#F7}

![Distribution of β~1~-adrenergic receptors in CRF-immunoreactive dendritic processes in the amygdala. A: β~1~-adrenergic receptors (β1-AR cyt) are shown located within the cytoplasmic compartment of a CRF-immunoreactive dendrite (CRF-d). B: β~1~-adrenergic receptors (β1-AR pm) are shown distributed along the plasma membrane of a CRF-immunoreactive dendrite (CRF-d). C: Some β~1~-adrenergic receptors are located within the cytoplasmic compartment, while some are located along the plasma membrane (β1-AR cyt + pm) of a CRF-immunoreactive dendrite (CRF-d). Arrowheads indicate immunogold labeling for β~1~-adrenergic receptors within the cytoplasmic compartment, while arrows point to β~1~-adrenergic receptors along the plasma membrane. Scale bars: 0.50 μm. Abbreviations: ud, unlabeled dendrite; m, mitochondria; ut, unlabeled terminal.](nihms349520f8){#F8}

###### 

Drug Treatment Groups

             [Drug Treatment]{.ul}: (14 days, 1x daily, i.p.)   [24 hrs after Final Drug Treatment (i.p.)]{.ul}   [44 hours after Final Drug Treatment (i.p.)]{.ul}
  ---------- -------------------------------------------------- ------------------------------------------------- ---------------------------------------------------
  Group SS   Saline (1 ml/kg)                                   Saline (1 ml/kg)                                  Saline (1 ml/kg)
  Group CS   Cocaine (20 mg/kg)                                 Saline (1 ml/kg)                                  Saline (1 ml/kg)
  Group SB   Saline (1 ml/kg)                                   Betaxolol (5 mg/kg)                               Betaxolol (5 mg/kg)
  Group CB   Cocaine (20 mg/kg)                                 Betaxolol (5 mg/kg)                               Betaxolol (5 mg/kg)
